statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sensex, Nifty erase gains after testing record highs; IT stocks decline

With the government and several cabinet ministers sworn in, all eyes will now be on portfolio allocation -- who gets to head which ministry.

Trade Spotlight: How should you trade Infosys, Coal India, Cipla, Divis Labs and others?

Despite elevated volatility, the market is expected to maintain an upward journey in the coming sessions, along with intermittent consolidation.

Cipla gets final USFDA approval injection used in treating hormonal tumors

Cipla Share Price | The injection is AP-rated therapeutic equivalent generic version of Somatuline Depot injection and is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrinciple tumors, the company said in a stock exchange filing.

ICICI Prudential Mutual fund buys 0.68% stake in Cipla

Among the promoter group of Cipla Limited, Samina Hamied sold a 1.1 percent stake.

Cipla shares soar 4% after promoter family unloads 2.53% stake

Cipla's block trade also comes with a lock-in period of 90 days for the sellers, reports suggested.

Accumulate Cipla; target of Rs 1405: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Cipla with a target price of Rs 1405 in its research report dated May 11, 2024.

Block deal in Cipla on cards, promoter entity may sell 2.53 percent stake worth Rs 2,637 crore

CNBC-Awaaz also learns that there is a lock-in for sellers for a period of 90 days after the scheduled block trade.

Sensex, Nifty turn green, fully recover from 1% intraday fall; analysts say 'exercise caution'

India VIX has more room to rise and the volatility could continue until the general election results are announced, say analysts

Cipla's strong US pipeline, steady Q4 earnings and hopes of easing regulatory snags drive bullishness

Cipla plans to launch 12 assets in peptides and complex generics space and 5 in the respiratory segment over FY25-27, which brokerages believe will secure its growth path for the next 3-4 years.

Open to market Eli Lilly’s weight loss drugs in India: Cipla CEO

Currently Cipla has the right to sell, promote and distribute two diabetes drugs of Eli Lilly in India

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Volume	4.69M
52-Wk High	1,600.00
52-Wk Low	1,132.00

CIPLA.NSE Cipla Ltd.

About

Feed

News

Sentiment

Fundamentals